See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Cefiderocol activity against resistant bacteria from patients with ventilator-associated pneumonia from European and US hospitals
Cefiderocol activity against resistant bacteria from patients with ventilator-associated pneumonia from European and US hospitals
Cefiderocol activity for carbapenem-non-susceptible bacteria from intensive care pneumonia patients
Cefiderocol activity for carbapenem-non-susceptible bacteria from intensive care pneumonia patients
Cefiderocol MIC against cefiderocol-resistant Acinetobacter baumannii can be affected by starting inoculum size
Cefiderocol MIC against cefiderocol-resistant Acinetobacter baumannii can be affected by starting inoculum size
Cefiderocol remains highly active against carbapenemase-producing Enterobacterales
Cefiderocol remains highly active against carbapenemase-producing Enterobacterales
Cefiderocol retains in vitro activity against Enterobacterales non-susceptible to β-lactam-β-lactamase inhibitor combinations
Cefiderocol retains in vitro activity against Enterobacterales non-susceptible to β-lactam-β-lactamase inhibitor combinations
Cefiderocol treatment in patients with Gram-negative bacterial infections: European results of the global retrospective observational PROVE study
Cefiderocol treatment in patients with Gram-negative bacterial infections: European results of the global retrospective observational PROVE study